Medication counselling with sodium glucose transporter 2 inhibitor therapy
Abstract
INTRODUCTION Diabetes counseling is an integral part of diabetes care. Termed in current practice as diabetes self-management education and support (DSME), this therapeutic intervention helps enhance the effective of diabetes pharmacotherapy as well. Modern standards allow providers of DSME to determine how best to deliver diabetes education to their target population. They clearly mention that “needs of the individual participant will determine which parts of the curriculum will be provided” to him or her. The curriculum is expected to be “dynamic and reflect current evidence and practice guidelines”. Core topics include “using medications safely and for maximum therapeutic effectiveness”.[1] Recent developments in diabetes pharmacotherapeutics allow a greater number of permutations and combinations with which one can manage diabetes. The use of newer, non-traditional drugs, however, comes with unique challenges as well. One such clinical situation has been described by Sethi et al. in this issue.[2] The exemplar described by the authors underscores the need for detailed history taking, and also for adequate patient education while prescribing any medication. The importance of person-centered and medication-relevant counseling cannot be underestimated. The unique features of medication-related counseling have been discussed earlier with respect to glucagon-like peptide 1 receptor agonists.[3] The sodium glucose transporter 2 inhibitor (SGLT2i) are a newly developed and…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.